AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03779633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linoladiol Estradiol
Description: Linoladiol Estradiol Initial dose (week 1): 1 application (2g Linoladiol = 0.2mg Estradiol) every day for the first week Maintenance dose 1 (week 2) : 1 application (2g Linoladiol = 0.2mg Estradiol) every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application (2g Linoladiol = 0.2mg Estradiol) twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks
Study NCT03779633 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vaginal cream
Description: Initial dose (week 1): 1 application every day for the first week Maintenance dose 1 (week 2) : 1 application every 48 hours the following week.~Maintenance dose 2 (week 3-6): 1 application twice per week the following 4 weeks.~Route of administration: intravaginally by means of a calibrated applicator before retiring at night Duration: 6 weeks
Study NCT01040689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for olodaterol BI1744)
Description: Placebo (olodaterol low and high dose)delivered by Respimat
Study NCT01040689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Tiotropium)
Description: Placebo (Tiotropium 18 mcg) delivered by HandiHaler
Study NCT01734278 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a non-interventional study.
Study NCT02197598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalmefene
Study NCT04745468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CRP apheresis
Description: Selective CRP apheresis by use of the PentraSorb-CRP adsorber
Study NCT00930709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A (Botox®, Allergan)
Description: Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
Study NCT00930709 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active strength training and stretching
Description: Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
Study NCT03966729 — intervention group
Intervention type: OTHER
Intervention: Time (outcome)
Study NCT01708538 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXL
Description: corneal crosslinking
Study NCT02690168 — intervention group
Intervention type: BEHAVIORAL
Intervention: Fasting
Description: 72 hour fasting
Study NCT01233180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gua Sha
Description: Single Gua Sha treatment of the neck and shoulder region
Study NCT01233180 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermotherapy
Description: Single use of a mud heat pad on the neck and shoulder region
Study NCT06134869 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Bone augmentation
Description: Dense PTFE membranes covering an allograft biomaterial were used without any attempt to passivate the flap
Study NCT03460288 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retraining (AAT)
Description: The training program is based upon the approach-avoidance task (AAT) and can be easily performed on a computer, laptop or tablet. There is a total of 20 pictures, 10 slot-machine gambling related pictures and 10 neutral pictures that were already used in a prior study (Wittekind et al., submitted). The pictures appear on the computer screen and have to be either pushed or pulled. Pushing and pulling depends on a masked instruction (not related to the content of the pictures, but to the color of the frame). All gambling-related pictures are framed with the color that is instructed to be pushed, all neutral pictures are framed with the color that is instructed to be pulled.
Study NCT03698422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine samples
Description: Subjects will be admitted to the Department of Nephrology, Herlev and Gentofte Hospital, Herlev, Denmark, for 24-hour observation with measurements of serum and urine at three-hour intervals.
Study NCT01040689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744) High
Description: High dose inhaled orally once daily from Respimat inhaler
Study NCT04820153 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Physical Activity Monitoring Device
Description: Participants will be provided a Fitbit Alta HR and wall charger. Each participant will be assigned a unique ID# at baseline and used to set-up the data acquisition. The Fitbit app will be set up on their smartphone to allow self-monitoring of activity. The Fitbit device includes both an accelerometer and heart rate monitor, capable of continuous measuring and storing data up to 5 days. Fitbit data will be passively downloaded through smartphone connection to Fitabase, a research friendly application and data management program. The Fitbit will be worn on the wrist every day during the course of the 16-week study, with instructions on self- monitoring, usage and maintenance. Participants will be monitored for Fitbit compliance by weekly phone calls; and monitoring of passively downloaded Fitbit data through Fitabase. Follow-up phone call at 3-months post-study will assess continued use of the Fitbit activity monitor.
Study NCT04820153 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle Redesign Coaching
Description: Participants will receive individualized goal setting and a guide to increase exercise at baseline and at week four visit. The Occupational therapist (OT) will administer a well published approach for promoting PA called Lifestyle Redesign which addresses physical, psychosocial and environmental barriers to health and incorporate self-care strategies and goal setting. Coaching will be administered by a bilingual OT and in Spanish. Based on studies examining PA and brain health, the OT will guide the participant through a goal setting process for moderate to vigorous intensity of physical activity including a specific guide plan to achieve these goals of 10,000 steps per day and/or 150 minutes/week of moderate to vigorous activity. Participants will also receive weekly calls from the study coordinator (overseen by OT) to review PA and goal setting for each week over the course of the 16-week study.
Study NCT01666145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advanced Image Guidance
Description: Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
Study NCT01517412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Study NCT01517412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Study NCT01517412 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Self-injector pen device (OptiClik®)
Study NCT01517412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-injector pen device (OptiClik®)
Study NCT01517412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: To be kept at stable dose (≥1.5 g/day) throughout the study.
Study NCT02289365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2000 mg of JBM-TC4 per day
Description: 2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
Study NCT02289365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3000 mg of JBM-TC4 per day
Description: 3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
Study NCT00754403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone and metformin
Description: Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
Study NCT02289365 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 3000 mg of PEG-400 per day
Description: 3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
Study NCT02284256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrocaps
Study NCT02284256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TachoSil
Study NCT01517412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: To be kept at stable dose (≥1.5 g/day) throughout the study.
Study NCT03002285 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cerebral Palsy group
Description: Group with Cerebral Palsy that performed the Fitts law in a computer task
Study NCT03002285 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Group with typical development that performed the Fitts law in a computer task
Study NCT00909519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxcinod
Description: naproxcinod 750 mg bid
Study NCT00909519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: Naproxen 500 mg bid
Study NCT00909519 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00909519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: furosemide
Description: furosemide
Study NCT00055575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine Nasal Spray
Study NCT02122926 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive discharge intervention
Description: The intervention is a multi-modal program consisting of the following:~1. Inpatient protocol for adjusting the discharge diabetes regimen;~2. Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;~3. Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);~4. Visiting nurse intervention after discharge;~5. Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;~6. Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and~7. Follow-up with PCP or endocrinologist within 1 week of discharge.
Study NCT03134612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8 mg
Study NCT03134612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocain 40 mg
Study NCT00586638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video game based training
Description: 36 one-hour sessions over 12 weeks
Study NCT00586638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video game based training
Description: 36 one-hour sessions over 12 weeks
Study NCT03774368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emergency contraception website
Description: Existing website with factual information about emergency contraception
Study NCT03774368 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emergency contraception video
Description: Existing video with factual information about emergency contraception
Study NCT02335203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Description: One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
Study NCT02335203 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
Study NCT01295307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Induction and consolidation therapy / conditioning therapy with Clofarabine
Study NCT02954887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study NCT03271320 — intervention group
Intervention type: OTHER
Intervention: appearance scales
Description: appearance scales : AVS; ASWAP; DAS 59
Study NCT04092803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The system includes a VR headset with VR software already loaded in to it.
Study NCT00768261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine (Namenda®)
Description: Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
Study NCT00768261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil (Aricept®)
Description: 5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
Study NCT02148263 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Study NCT01040689 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium 18 mcg
Description: 18mcg inhaled once daily from Handihaler
Study NCT04174768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Description: Bariatric surgery including sleeve gastrectomy and Roux-en-Y gastric bypass
Study NCT01293084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.12% saline
Description: 5mL of 0.12% saline inhaled once over 20 minutes
Study NCT01293084 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7% saline
Description: 5mL 7% saline inhaled once over 20 minutes
Study NCT01877941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Artery Catheter (PAC)
Description: A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
Study NCT01877941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal Cardiac Output Monitor (ECOM)
Description: An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
Study NCT01877941 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Estimated Continuous Cardiac Output (esCCO)
Description: Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
Study NCT02796612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Patients do not receive any interventions but are treated according to current standard of care.
Study NCT02796612 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: no intervention
Description: Patients do not receive any interventions but are treated according to current standard of care.
Study NCT02796612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: delivery of a take-home brochure
Description: Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
Study NCT02796612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient care by a psychologically trained physician
Description: The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
Study NCT04712487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiological culture, viral PCR, histopathological analysis
Description: Intervertebral disc tissue was sent to the laboratory for further analysis:~Microbiological culture: Detection of bacterial growth Viral PCR: Detection of Herpes-Simplex-Type 1 virus, Herpes-Simplex-Type 2 virus, Cytomegalovirus Histopathological analysis: Inflammation signs of disc tissue
Study NCT02685111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
Study NCT02685111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-filgrastim
Description: Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
Study NCT04035538 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-320, D012
Description: R: D012 1tablet, QD, PO T: CKD-320 2tablets, QD, PO
Study NCT02569021 — intervention group
Intervention type: DEVICE
Intervention: Biphasic DBS stimulation
Description: The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.~1. Current best/optimized DBS setting (considered baseline)~2. DBS off for 30 minutes as a washout period~3. Biphasic pulse stimulation mode (assessment at 0.5hr)~4. Biphasic pulse stimulation mode (assessment at 1hr)~5. Biphasic pulse stimulation mode (assessment at 2hr)~6. Biphasic pulse stimulation mode (assessment at 3hr)
Study NCT02569021 — intervention group
Intervention type: OTHER
Intervention: Unified Parkinson's Disease Rating Scale
Description: UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
Study NCT02569021 — intervention group
Intervention type: OTHER
Intervention: Tremor Rating Scale
Description: TRS is used by neurologists to rate the severity of a tremor.
Study NCT02569021 — intervention group
Intervention type: DEVICE
Intervention: Kinesia accelerometer
Description: The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
Study NCT02569021 — intervention group
Intervention type: DEVICE
Intervention: Trigno wireless system
Description: The Trigno system measure muscle contractions.
Study NCT02569021 — intervention group
Intervention type: OTHER
Intervention: GaitRite walking assessment.
Description: GaitRite records a patients gait pattern.
Study NCT04397315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy to the level of canal orifices
Description: Pulp tissue will be removed till the level of canal orifices.
Study NCT04397315 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulpotomy up to superficial 2-3 mm of pulp chamber
Description: Only superficial pulp from the chamber will be removed
Study NCT02270801 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhTPO
Description: rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10\^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
Study NCT00721617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
Study NCT01962090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic Spine Thrust in Seated Position
Description: The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
Study NCT00721617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
Study NCT00721617 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral fat load
Description: Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).